Nevro Corp (NVRO) Given Consensus Rating of “Buy” by Analysts
Shares of Nevro Corp (NASDAQ:NVRO) have been given a consensus rating of “Buy” by the eleven ratings firms that are covering the firm. Eleven analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have covered the stock in the last year is $104.00.
A number of equities research analysts have weighed in on the company. B. Riley assumed coverage on Nevro Corp in a research report on Wednesday, September 21st. They issued a “buy” rating and a $114.00 target price for the company. Zacks Investment Research upgraded Nevro Corp from a “hold” rating to a “buy” rating and set a $109.00 target price for the company in a research report on Friday, August 12th. William Blair assumed coverage on Nevro Corp in a research report on Tuesday, July 19th. They issued an “outperform” rating for the company. JMP Securities upped their target price on Nevro Corp from $90.00 to $110.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 9th. Finally, JPMorgan Chase & Co. increased their price objective on Nevro Corp from $84.00 to $100.00 and gave the company an “overweight” rating in a research report on Tuesday, August 9th.
In other Nevro Corp news, VP Doug Alleavitch sold 1,000 shares of the business’s stock in a transaction on Friday, July 29th. The shares were sold at an average price of $85.00, for a total transaction of $85,000.00. Following the sale, the vice president now directly owns 7,961 shares of the company’s stock, valued at approximately $676,685. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Michael F. Demane sold 13,333 shares of the business’s stock in a transaction on Friday, July 29th. The shares were sold at an average price of $84.00, for a total transaction of $1,119,972.00. Following the sale, the director now directly owns 505,919 shares in the company, valued at $42,497,196. The disclosure for this sale can be found here.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/nevro-corp-nvro-given-consensus-rating-of-buy-by-analysts.html
A number of hedge funds have recently made changes to their positions in NVRO. Essex Investment Management Co. LLC increased its stake in shares of Nevro Corp by 40.9% in the second quarter. Essex Investment Management Co. LLC now owns 12,860 shares of the company’s stock valued at $949,000 after buying an additional 3,735 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Nevro Corp during the second quarter valued at about $323,000. Emerald Acquisition Ltd. purchased a new stake in shares of Nevro Corp during the second quarter valued at about $6,949,000. First Trust Advisors LP purchased a new stake in shares of Nevro Corp during the second quarter valued at about $2,406,000. Finally, Swiss National Bank increased its stake in shares of Nevro Corp by 32.2% in the second quarter. Swiss National Bank now owns 33,700 shares of the company’s stock valued at $2,486,000 after buying an additional 8,200 shares during the period.
Shares of Nevro Corp (NASDAQ:NVRO) traded up 0.70% during midday trading on Thursday, reaching $99.18. The company’s stock had a trading volume of 258,370 shares. The company’s market cap is $2.83 billion. The stock’s 50-day moving average price is $97.64 and its 200-day moving average price is $79.50. Nevro Corp has a 12-month low of $36.51 and a 12-month high of $106.93.
Nevro Corp (NASDAQ:NVRO) last released its earnings results on Monday, August 8th. The company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.16. The firm earned $55.40 million during the quarter, compared to analyst estimates of $45.11 million. The business’s revenue for the quarter was up 385.5% compared to the same quarter last year. On average, analysts expect that Nevro Corp will post ($1.42) EPS for the current fiscal year.
About Nevro Corp
Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain.
Receive News & Ratings for Nevro Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp and related companies with MarketBeat.com's FREE daily email newsletter.